During the last session, Neumora Therapeutics Inc (NASDAQ:NMRA)’s traded shares were 0.59 million, with the beta value of the company hitting 2.79. At the end of the trading day, the stock’s price was $1.03, reflecting an intraday loss of -6.36% or -$0.07. The company’s market capitalization is $166.84M, and the average intraday trading volume over the past 10 days was 1.27 million shares, and the average trade volume was 3.32 million shares over the past three months.
Neumora Therapeutics Inc (NMRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.11. NMRA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.38.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Neumora Therapeutics Inc (NMRA) registered a -6.36% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.36% in intraday trading to $1.03, hitting a weekly high. The stock’s 5-day price performance is -8.85%, and it has moved by -33.55% in 30 days. Based on these gigs, the overall price performance for the year is -91.83%. The short interest in Neumora Therapeutics Inc (NASDAQ:NMRA) is 12.89 million shares and it means that shorts have 9.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 65.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $4 respectively. As a result, NMRA is trading at a discount of -288.35% off the target high and -94.17% off the low.
While earnings are projected to return 4.29% in 2025, the next five years will return 8.30% per annum.
NMRA Dividends
Neumora Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Neumora Therapeutics Inc insiders own 27.52% of total outstanding shares while institutional holders control 71.99%, with the float percentage being 99.33%. FMR LLC is the largest shareholder of the company, while 182.0 institutions own stock in it. As of 2024-06-30, the company held over 8.62 million shares (or 5.4235% of all shares), a total value of $84.76 million in shares.
The next largest institutional holding, with 7.65 million shares, is of SOFTBANK GROUP CORP.’s that is approximately 4.8099% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $75.17 million.
Also, the Mutual Funds coming in first place with the largest holdings of Neumora Therapeutics Inc (NMRA) shares are SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that SMALLCAP WORLD FUND INC owns about 3.7 shares. This amounts to just over 2.28 percent of the company’s overall shares, with a $3.81 million market value. The same data shows that the other fund manager holds slightly less at 2.32, or about 1.43% of the stock, which is worth about $2.39 million.
